Development of Personalized Colonic Drug Delivery Systems Prepared by 3D-Printing Technology

Abstract:

Colonic drug delivery systems (CDDS) show several advantages for treatment of inflammatory bowel disease such as improving the clinical outcomes and minimizing side effects of corticosteroids. However, variation of the patient's gastrointestinal tract (GIT) in terms of transit time and pH causes the fluctuation of the drug releasing site in the GIT resulting in low therapeutic efficiency. Consequently, 3D-printing techniques have been applied for preparation of personalized colonic drug delivery systems in this study. Prednisolone was selected as a model drug and prepared in the form of a core tablet. Polylactic acid (PLA) and polyvinyl alcohol (PVA) were printed as a tablet housing and a drug control release plug, respectively. A two-factor full factorial model was utilized to design the experiment and partial least square regression (PLS) models were generated to reveal and predict drug release time of the system. From the results, only thickness of the PVA plug significantly affected the drug release at sampling times of 5, 6, 10, and 24 h. The relations between thickness of the plug and drug releases at 5, 6, and 10 h are quadratic but that of 24 h is linear. The relation between thickness of the plug and drug releases is quadratic. The drug could not be completely released in 24 h because the drug was entrapped by PVA gel. The search results show the possibility to utilize the PLS models to modify drug release time for individual patients. However, alteration of plug polymer is a suggestion to obtain complete drug release.

• Periodical: Key Engineering Materials (Volume 901)
• Pages: 144-150
• DOI: https://doi.org/10.4028/www.scientific.net/KEM.901.144
• Online since: October 2021
• Authors: Tanikan Sangnim, Arunlux Tangpanithanon, Maythawee Khamtheantong, Jintanan Charoenwai, Kampanart Huanbutta*
• Keywords: 3D Printing, Colonic Drug Delivery, Design of Experiment, Full Factorial Design, Fused Deposition Modeling, Inflammatory Bowel Disease, Personalized Dosage Forms

References

[1] T. Sairenji, K.L. Collins, D. V Evans, An update on inflammatory bowel disease, Prim. Care. 44 (2017) 673–692.

DOI: 10.1016/j.pop.2017.07.010

[2] S. Alatab, S.G. Sepanlou, K. Ikuta, H. Vahedi, C. Bisignano, S. Safiri, A. Sadeghi, M.R. Nixon, A. Abdoli, H. Abolhassani, The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet Gastroenterol. Hepatol. 5 (2020) 17–30.

DOI: 10.1016/s2215-0366(21)00395-3

[3] A.B. Pithadia, S. Jain, Treatment of inflammatory bowel disease (IBD), Pharmacol. Reports. 63 (2011) 629–642.

DOI: 10.1016/s1734-1140(11)70575-8

[4] N. Vakil, M. Sparberg, Steroid-related osteonecrosis in inflammatory bowel disease, Gastroenterology. 96 (1989) 62–67.

DOI: 10.1016/0016-5085(89)90764-6

[5] A.H. Teruel, I. Gonzalez-Alvarez, M. Bermejo, V. Merino, M.D. Marcos, F. Sancenon, M. Gonzalez-Alvarez, R. Martinez-Mañez, New insights of oral colonic drug delivery systems for inflammatory bowel disease therapy, Int. J. Mol. Sci. 21 (2020) 6502.

DOI: 10.3390/ijms21186502

[6] M. Z. I. Khan, H. P. Štedul, N. Kurjaković, A pH-dependent colon-targeted oral drug delivery system using methacrylic acid copolymers. II. Manipulation of drug release using Eudragit® L100 and Eudragit® S100 combinations, Drug Dev. Ind. Pharm. 26 (2000) 549-554.

DOI: 10.1081/ddc-100101266

[7] D. Cai, C. Han, C. Liu, X. Ma, J. Qian, J. Zhou, Y. Li, Y. Sun, C. Zhang, W. Zhu, Chitosan-capped enzyme-responsive hollow mesoporous silica nanoplatforms for colon-specific drug delivery, Nanoscale Res. Lett. 15 (2020) 1-13.

DOI: 10.1186/s11671-020-03351-8

[8] S. Bertoni, A. Machness, M. Tiboni, R. Bártolo, H.A. Santos, Reactive oxygen species responsive nanoplatforms as smart drug delivery systems for gastrointestinal tract targeting, Biopolymers 111 (2020) e23336.

DOI: 10.1002/bip.23336

[9] Y.I. Jeong, T. Ohno, Z. Hu, Y. Yoshikawa, N. Shibata, S. Nagata, K. Takada, Evaluation of an intestinal pressure-controlled colon delivery capsules prepared by a dipping method, J. Control. Release 71 (2001) 175-182.

DOI: 10.1016/s0168-3659(01)00211-5

[10] K. Niwa, T. Takaya, T. Morimoto, K. Takada, Preparation and evaluation of a time-controlled release capsule made of ethylcellulose for colon delivery of drugs, J. Drug Target. 3 (1995) 83-89.

DOI: 10.3109/10611869509059209

[11] J. Nunthanid, K. Huanbutta, M. Luangtana-Anan, P. Sriamornsak, S. Limmatvapirat, S. Puttipipatkhachorn, Development of time-, pH-, and enzyme-controlled colonic drug delivery using spray-dried chitosan acetate and hydroxypropyl methylcellulose, Eur. J. Pharm. Biopharm. 68 (2008) 253–259.

DOI: 10.1016/j.ejpb.2007.05.017

[12] J. Zhang, A.Q. Vo, X. Feng, S. Bandari, M.A. Repka, Pharmaceutical additive manufacturing: a novel tool for complex and personalized drug delivery systems, AAPS PharmSciTech. 19 (2018) 3388–3402.

DOI: 10.1208/s12249-018-1097-x

[13] K. Huanbutta, P. Sriamornsak, T. Kittanaphon, K. Suwanpitak, N. Klinkesorn, T. Sangnim, Development of a zero-order kinetics drug release floating tablet with anti–flip-up design fabricated by 3D-printing technique, J. Pharm. Investig. 51 (2021) 213-222.

DOI: 10.1007/s40005-020-00507-7

[14] R.T.L. Ferreira, I.C. Amatte, T.A. Dutra, D. Bürger, Experimental characterization and micrography of 3D printed PLA and PLA reinforced with short carbon fibers. Compos. B. Eng. 124 (2017) 88-100.

DOI: 10.1016/j.compositesb.2017.05.013

[15] T. Tagami, K. Fukushige, E. Ogawa, N. Hayashi, T. Ozeki, 3D printing factors important for the fabrication of polyvinylalcohol filament-based tablets, Biol. Pharm. Bull. 40 (2017) 357-364.

DOI: 10.1248/bpb.b16-00878

[16] S. Jana, K.K. Sen, Gellan gum/PVA interpenetrating network micro-beads for sustained drug delivery, Mater. Today Proc. 11 (2019) 614–619.

DOI: 10.1016/j.matpr.2019.03.018

[17] I. M. Fukuda, C. F. F Pinto, C. D. S. Moreira, A. M. Saviano, F. R. Lourenço, Design of experiments (DoE) applied to pharmaceutical and analytical quality by design (QbD). Braz. J. Pharm. Sci. 54 (2018) 1-16.

DOI: 10.1590/s2175-97902018000001006